Literature DB >> 11824875

Open access follow-up for lung cancer: patient and staff satisfaction.

J W Adlard1, J Joseph, C V Brammer, G E Gerrard.   

Abstract

The majority of patients with lung cancer have incurable disease from presentation and a survival measured in months. Treatments offered to these patients are aimed at the palliation of symptoms with either radiotherapy or chemotherapy, or with supportive measures. It has been traditional to offer regular outpatient follow-up after initial palliative treatment. Further treatment options, which may be limited, are usually reserved for the recurrence of troublesome symptoms. A pilot 'open access' lung cancer clinic has been set up. Rather than have regular follow-up at the hospital, patients who have completed initial palliative treatments are discharged to the community with follow-up by their general practitioner and Macmillan nurse. Review at the open access clinic can be arranged at short notice if requested by the patient, carers, general practitioner or Macmillan nurse. The outcomes and level of satisfaction of patients, their relatives and staff to this method of follow-up were found to be positive. Open access follow-up may be useful for many patients after the completion of initial palliative treatment.

Entities:  

Mesh:

Year:  2001        PMID: 11824875     DOI: 10.1053/clon.2001.9302

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  The success of data collection in the palliative setting--telephone or clinic follow-up?

Authors:  Peiman Haddad; Paula Wilson; Rebecca Wong; Diane Williams; Neena Sharma; Freidele Soban; Michael McLean; Wilfred Levin; Andrea Bezjak
Journal:  Support Care Cancer       Date:  2003-06-17       Impact factor: 3.603

2.  Evaluation of a patient-initiated review system in rheumatoid arthritis: an implementation trial protocol.

Authors:  Priyamvada Paudyal; Mark Perry; Sue Child; Christian A Gericke
Journal:  BMC Musculoskelet Disord       Date:  2012-07-09       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.